Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 21,412 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase II Clear all

Conditions: Macular Edema, Branch Retinal Vein Occlusion
Interventions: Ranibizumab, Peripheral Laser; Drug · Procedure
Lead sponsor: Retina Associates of Florida, P.A.; Other
Eligibility: 18 Years to 90 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer
Interventions: Placebo, Curcumin; Drug
Lead sponsor: Andrew H Miller; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chronic Hepatitis C
Interventions: Nitazoxanide, Placebo, Peginterferon alfa-2a, Ribavirin; Drug · Biological
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 10
States / cities: Palo Alto, California • New Haven, Connecticut • Bay Pines, Florida + 6 more

Conditions: Acute Myeloid Leukemia, Adult, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, Relapsed, Adult
Interventions: Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO); Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Ann Arbor Stage I Small Lymphocytic Lymphoma, Ann Arbor Stage II Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene, Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lenalidomide, Pneumococcal Polyvalent Vaccine; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 79 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Palmoplantar Pustulosis
Interventions: Imsidolimab, Placebo; Biological · Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Encino, California + 15 more

Conditions: Metastatic Uveal Melanoma
Interventions: Defactinib Hydrochloride, Raf/MEK Inhibitor VS-6766, Biopsy; Drug · Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions: fenretinide, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Septic Shock
Interventions: Hydroxocobalamin, Placebo; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Lung Cancer, Non-small Cell Lung Cancer
Interventions: Vorinostat, Pembrolizumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Rectal Cancer
Interventions: Etrumadenant (AB928), Radiation therapy, FOLFOX regimen, Zimberelimab (AB122); Drug · Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 3
States / cities: New York, New York

Conditions: Multiple Brain Metastases
Interventions: BMX-001, Whole Brain Radiation Therapy; Drug · Radiation
Lead sponsor: BioMimetix JV, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 4
States / cities: Lexington, Kentucky • Detroit, Michigan • Durham, North Carolina + 1 more

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Ranibizumab (Lucentis), Argon Laser; Drug · Procedure
Lead sponsor: Rocky Mountain Retina Consultants; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Chronic Prostatitis, Chronic Pelvic Pain Syndrome
Interventions: AQX-1125 200 mg, Placebo; Drug
Lead sponsor: Aquinox Pharmaceuticals (Canada) Inc.; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 23
States / cities: Homewood, Alabama • Mobile, Alabama • Tucson, Arizona + 19 more

Conditions: Glioblastoma, Glioblastoma Multiforme
Interventions: Disulfiram, Copper gluconate, Temozolomide; Drug · Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Interventions: Giredestrant, Abemaciclib, Ipatasertib, Inavolisib, Ribociclib, Everolimus, Samuraciclib, PH FDC SC, Palbociclib, Atezolizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 12
States / cities: Duarte, California • Irvine, California • San Francisco, California + 9 more

Conditions: Metastatic Breast Cancer
Interventions: Letrozole, Trastuzumab; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • St Louis, Missouri + 1 more

Conditions: Waldenstrom's Macroglobulinemia
Interventions: CC-5103 (lenalidomide), Rituximab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Cervical Cancer
Interventions: cisplatin, paclitaxel, brachytherapy, radiation therapy; Drug · Radiation
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 31
States / cities: Phoenix, Arizona • Newark, Delaware • Chicago, Illinois + 26 more

Conditions: Advanced Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions: Abiraterone, Biospecimen Collection, Darolutamide, Prednisone; Drug · Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Male only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Urothelial Carcinoma
Interventions: Cabazitaxel, Neulasta, CT Scan, Blood Draw; Drug · Procedure · Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 3
States / cities: Bethesda, Maryland • Philadelphia, Pennsylvania

Conditions: Glioblastoma
Interventions: G-202; Drug
Lead sponsor: GenSpera, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Follicular Helper T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Duvelisib, Positron Emission Tomography, Survey Administration; Procedure · Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
Interventions: nab-sirolimus; Drug
Lead sponsor: Aadi Bioscience, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 159
States / cities: Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 137 more

Search by objective public record fields.

REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study

Phase II Study of Curcumin vs Placebo for Chemotherapy-Treated Breast Cancer Patients Undergoing Radiotherapy

Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients

CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis

Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma

Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme

A Trial of Vitamin B12 in Septic Shock

Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy

Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema

Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC

CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia

Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy

Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma

Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)